ZBH

+ Watchlist + Portfolio

Zimmer Biomet Holdings, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $100.74
52-Week Range: $79.12 – $108.29
Market Cap: $18.88B
P/E (TTM): 24.02
EPS (TTM): 4.12
Dividend Yield: 0.95%

Advanced Metrics

Price/Book: 1.49
PEG Ratio: 0.67
Return on Equity: 6.41%
Return on Assets: 3.96%
Gross Margin: 69.88%
Operating Margin: 17.96%
Profit Margin: 9.48%
Current Ratio: 1.69
Debt/Equity: 0.60
Total Debt: $7.60B
Free Cash Flow: $1.09B
Revenue Growth: 4.80%
Earnings Growth: 33.80%
Enterprise Value: $26.02B

ZBH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$6.94B	$7.39B	$7.68B	$8.23B
Cost of Revenue	$2.02B	$2.08B	$2.19B	$2.49B
Gross Profit	$4.92B	$5.31B	$5.49B	$5.74B
Research & Development	$406.00M	$458.70M	$437.40M	$458.50M
Selling, General & Admin	$2.76B	$2.84B	$2.93B	$3.26B
Operating Expenses	$3.73B	$3.86B	$3.96B	$4.38B
Operating Income	$1.19B	$1.45B	$1.53B	$1.36B
EBITDA	$1.49B	$2.22B	$2.25B	$2.22B
Pretax Income	$403.50M	$1.07B	$1.04B	$830.80M
Income Tax	$112.30M	$42.20M	$131.40M	$125.70M
Net Income	$231.40M	$1.02B	$903.80M	$705.10M
Diluted EPS	1.10	4.88	4.43	3.55
Diluted Shares	210.30M	209.70M	203.90M	198.70M

ZBH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$375.70M	$415.80M	$525.50M	$591.90M
Receivables	$1.38B	$1.44B	$1.48B	$1.70B
Inventory	$2.15B	$2.39B	$2.24B	$2.29B
Current Assets	$4.43B	$4.61B	$4.67B	$5.12B
Total Assets	$21.07B	$21.50B	$21.37B	$23.09B
Current Liabilities	$2.36B	$2.86B	$2.45B	$2.58B
Long-Term Debt	$5.15B	$4.87B	$5.34B	$6.93B
Total Debt	$5.70B	$5.77B	$6.20B	$7.52B
Total Liabilities	$9.04B	$9.01B	$8.89B	$10.39B
Retained Earnings	$9.56B	$10.38B	$11.10B	$11.61B
Shareholders' Equity	$12.02B	$12.48B	$12.47B	$12.70B
Working Capital	$2.07B	$1.75B	$2.22B	$2.54B
Net Debt	$5.32B	$5.35B	$5.68B	$6.93B

ZBH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$1.28B	$1.58B	$1.50B	$1.70B
Capital Expenditure	-$217.60M	-$394.50M	-$356.80M	-$276.90M
Free Cash Flow	$1.07B	$1.19B	$1.14B	$1.42B
Depreciation & Amortisation	$926.40M	$951.70M	$996.30M	$1.09B
Stock-Based Compensation	$105.00M	$99.80M	$101.00M	$90.20M
Investing Cash Flow	-$529.20M	-$778.90M	-$888.10M	-$1.98B
Financing Cash Flow	-$843.80M	-$763.50M	-$484.50M	$326.00M
Dividends Paid	-$201.20M	-$200.90M	-$196.00M	-$190.30M
Share Repurchases	-$126.40M	-$692.20M	-$868.00M	-$487.00M
Net Change in Cash	-$88.30M	$39.20M	$126.80M	$47.40M

ZBH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$1.91B	$2.08B	$2.00B	$2.24B	$2.09B
Cost of Revenue	$549.80M	$592.20M	$559.30M	$792.40M	$576.20M
Gross Profit	$1.36B	$1.49B	$1.44B	$1.45B	$1.51B
Research & Development	$110.60M	$113.30M	$115.90M	$118.70M	$103.40M
Selling, General & Admin	$758.80M	$814.80M	$811.40M	$872.30M	$849.90M
Operating Expenses	$1.02B	$1.09B	$1.10B	$1.17B	$1.12B
Operating Income	$338.90M	$396.40M	$338.30M	$282.60M	$395.10M
EBITDA	$549.60M	$575.70M	$638.20M	$453.90M	$640.10M
Pretax Income	$229.00M	$224.60M	$279.20M	$98.00M	$301.30M
Income Tax	$46.50M	$71.20M	$48.00M	-$39.90M	$63.00M
Net Income	$182.00M	$152.80M	$230.90M	$139.30M	$238.10M
Diluted EPS	0.91	0.77	1.16	—	1.22
Diluted Shares	199.70M	198.30M	198.80M	—	195.80M

ZBH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$1.38B	$556.90M	$1.29B	$591.90M	$424.20M
Receivables	$1.53B	$1.61B	$1.60B	$1.70B	$1.73B
Inventory	$2.24B	$2.45B	$2.48B	$2.29B	$2.25B
Current Assets	$5.59B	$5.05B	$5.83B	$5.12B	$4.96B
Total Assets	$22.18B	$22.87B	$23.49B	$23.09B	$22.72B
Current Liabilities	$2.29B	$2.70B	$2.40B	$2.58B	$2.86B
Long-Term Debt	$6.58B	$6.75B	$7.51B	$6.93B	$6.30B
Total Debt	$7.18B	$7.57B	$8.11B	$7.52B	$7.47B
Total Liabilities	$9.78B	$10.33B	$10.72B	$10.39B	$10.04B
Retained Earnings	$11.23B	$11.34B	$11.52B	$11.61B	$11.80B
Shareholders' Equity	$12.40B	$12.53B	$12.76B	$12.70B	$12.67B
Working Capital	$3.30B	$2.35B	$3.43B	$2.54B	$2.10B
Net Debt	$5.79B	$7.02B	$6.82B	$6.93B	$7.05B

ZBH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$382.80M	$378.20M	$418.70M	$517.40M	$359.40M
Capital Expenditure	-$47.00M	-$80.10M	-$65.00M	-$84.80M	-$75.30M
Free Cash Flow	$335.80M	$298.10M	$353.70M	$432.60M	$284.10M
Depreciation & Amortisation	$254.40M	$271.80M	$283.60M	$284.00M	$270.00M
Stock-Based Compensation	$19.60M	$21.20M	$25.30M	$24.10M	$24.20M
Investing Cash Flow	-$106.00M	-$1.38B	-$163.30M	-$322.00M	-$159.00M
Financing Cash Flow	$575.40M	$163.80M	$483.80M	-$897.00M	-$369.20M
Dividends Paid	-$47.80M	-$47.50M	-$47.50M	-$47.50M	-$46.90M
Share Repurchases	-$229.80M	-$7.20M	$0.00	-$250.00M	-$250.10M
Net Change in Cash	$852.00M	-$842.20M	$739.20M	-$701.60M	-$168.80M

Market Snapshot

About

Zimmer Biomet Holdings is a global leader in musculoskeletal healthcare, specializing in the design, manufacture, and marketing of orthopedic reconstructive products, sports medicine, biologics, extremities, and trauma products. The company provides solutions for knee, hip, shoulder, elbow, foot, and ankle replacement, as well as dental implants and related surgical products. Zimmer Biomet serves healthcare professionals and patients in more than 100 countries worldwide.